| Literature DB >> 19543405 |
Abstract
Acetylcholine (ACh) contributes to learning processes by modulating cortical plasticity in terms of intensity of neuronal activity and selectivity properties of cortical neurons. However, it is not known if ACh induces long term effects within the primary visual cortex (V1) that could sustain visual learning mechanisms. In the present study we analyzed visual evoked potentials (VEPs) in V1 of rats during a 4-8 h period after coupling visual stimulation to an intracortical injection of ACh analog carbachol or stimulation of basal forebrain. To clarify the action of ACh on VEP activity in V1, we individually pre-injected muscarinic (scopolamine), nicotinic (mecamylamine), alpha7 (methyllycaconitine), and NMDA (CPP) receptor antagonists before carbachol infusion. Stimulation of the cholinergic system paired with visual stimulation significantly increased VEP amplitude (56%) during a 6 h period. Pre-treatment with scopolamine, mecamylamine and CPP completely abolished this long-term enhancement, while alpha7 inhibition induced an instant increase of VEP amplitude. This suggests a role of ACh in facilitating visual stimuli responsiveness through mechanisms comparable to LTP which involve nicotinic and muscarinic receptors with an interaction of NMDA transmission in the visual cortex.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19543405 PMCID: PMC2696093 DOI: 10.1371/journal.pone.0005995
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Design of the experiment.
(A) Schematic diagram illustrating the chronic implantation of the recoding electrode in V1 and the push-pull cannula guide as well as the lateral stimulation of the retina with a horizontal grating displayed on a computer screen. The push-pull cannula guide and the recording electrode guide were implanted in visual cortex 2 days before VEP recording. (B) Visual stimulation. Rats were stimulated by displaying trains of sinusoidal horizontal grating (100 ms, 0.033 Hz, contrast 100%) for 8 cycles. Each cycle consisted of 10 min visual stimulation every 30 min. The VEP was obtained by averaging the 20 single electrophysiological signals evoked by the 20 presentations of the grating during the stimulation period. (C) Histology of the injection and recording sites. Schematic coronal section at the site of recording and cresyl violet-stained coronal section showing electrolytic lesion indicating position of electrode tip (arrow) and location of the infusion cannula (arrow head). Electrode and cannula tips are adjacent.
Figure 2Effects of cholinergic system activation on VEPs amplitude.
Cholinergic activation was performed through pharmacological injection or electrical stimulation paired with visual stimuli. (A) Representative wave of the VEP recorded before (grey line) and after (black line) CCh injection or HDB stimulation. The recorded wave was composed of a negative peak followed by a positive deviation representative of layer 4 field potentials trace. (B) Long-term effect on VEP amplitude of CCh infused in V1 (open square) or of HDB stimulation (triangle). After 2 periods of baseline recording (0 and 30 min), application of CCh or HDB stimulation (indicated by arrow) produces an increase of VEP amplitude observed for several hours after CCh infusion or HDB stimulation. Error bars indicate the SD values.
Amplitude of VEP normalized after CCh injection or HDB stimulation and drug treatment.
| Amplitude (%) | 0 min | 30 min | 60 min | 90 min | 120 min | 150 min | 180 min | 210 min |
|
| ||||||||
|
| 100 | 99±11 | 86±19 | 91±17 | 83±29 | 84±15 | 94±12 | 92±11 |
|
| 100 | 101±11 | 127±39 | 151±41 | 142±32 | 144±12 | 156±21 | 149±16 |
|
| 100 | 95±04 | 154±03 | 144±03 | 140±21 | 159±02 | 126±19 | 147±22 |
|
| 100 | 90±14 | 54±02 | 89±14 | 78±15 | 86±19 | 95±18 | 114±08 |
|
| 100 | 95±08 | 130±45 | 182±40 | 165±17 | 148±24 | 162±04 | 153±25 |
|
| ||||||||
|
| 100 | 95±15 | 105±13 | 92±12 | 115±18 | 122±14 | 130±18 | 112±13 |
|
| 100 | 78±26 | 108±34 | 93±24 | 64±05# | 72±16# | 84±29# | 85±22# |
|
| 100 | 99±10 | 115±10 | 101±10 | 77±21# | 97±08# | 90±09# | 91±11# |
|
| 100 | 102±06 | 94±07 | 83±15 | 152±29# | 100±22# | 86±06# | 131±08# |
|
| 100 | 106±22 | 91±08 | 111±16 | 88±14# | 108±18 | 100±12# | 81±15# |
Values are expressed in mean±SD. For the first set of experiment (cholinergic enhancement) CCh infusion and HDB stimulation were administrated at t = 60 min. For pharmacological treatment, antagonists were injected at t = 60 min followed by CCh at t = 120 min.
p<0.05, compared to control, ANOVA and LSD post-hoc.
p<0.05, compared to aCSF+CCh, ANOVA and LSD post-hoc.
Latency of VEP after CCh injection or HDB stimulation and drug treatment.
| Latency (ms) | 0 min | 30 min | 60 min | 90 min | 120 min | 150 min | 180 min | 210 min |
|
| ||||||||
|
| 36±3 | 35±3 | 37±3 | 35±4 | 35±2 | 33±4 | 34±3 | 35±4 |
|
| 37±3 | 37±2 | 36±4 | 34±3 | 29±3 | 26±5 | 31±3 | 31±3 |
|
| 35±4 | 32±2 | 33±3 | 33±3 | 35±3 | 33±4 | 36±1 | 35±3 |
|
| 37±1 | 41±1 | 40±2 | 40±2 | 35±4 | 38±3 | 39±5 | 37±2 |
|
| 38±1 | 38±3 | 35±1 | 33±1 | 33±1 | 35±5 | 33±3 | 36±1 |
|
| ||||||||
|
| 38±2 | 37±4 | 35±4 | 33±3 | 36±3 | 32±3 | 32±3 | 35±2 |
|
| 38±5 | 37±2 | 41±1 | 39±3 | 43±5 | 40±6 | 44±5 | 39±6 |
|
| 39±1 | 38±3 | 38±2 | 37±6 | 46±3 | 45±4 | 30±4 | 38±4 |
|
| 40±2 | 41±4 | 39±2 | 37±4 | 36±4 | 37±3 | 39±3 | 37±2 |
|
| 39±3 | 36±4 | 36±2 | 34±3 | 38±2 | 38±5 | 31±4 | 30±6 |
Values are expressed in mean±SD of ms after the stimulation artefact. There was no effect of the treatment on latency.
Figure 3VEP amplitude changes after pharmacological infusion of drugs in V1.
Effects of scopolamine (B, Sco+CCh), CPP (C, CPP+CCh), mecamylamine (D, Mec+CCh) or MLA (E, MLA+CCh) infusion prior to CCh administration are shown compared to aCSF+CCh injected animals as control group (black histograms). The long term enhancement of VEP amplitude is abolished in an identical manner by scopolamine, CPP and mecamylamine, suggesting that mAChR and nAChR could act upstream of NMDAR intracellular pathways. Drug infusion time points are indicated by black arrows.